FDA Approves Lower Dose Narcan Spray
FDA has approved an Adapt Pharma NDA for Narcan (naloxone) Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory or central nervous system depression. Last year, the agency approved Narcan Nasal Spray 4mg under the expedited review and approval process. Both products are intended for emergency use, and patients who overdose still require emergency care afterward, the company says.